Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects

被引：0
|
作者：
Yong Zeng
Yi-jing He
Fu-yuan He
Lan Fan
Hong-hao Zhou
机构：
[1] Pharmacogenetics Research Institute,
[2] Institute of Clinical Pharmacology,undefined
[3] Central South University,undefined
来源：
Acta Pharmacologica Sinica | 2009年 / 30卷
关键词：
bifendate; cyclosporine; pharmacokinetics; CYP3A4; 18B;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：478 / 484
页数：6
相关论文
共 50 条
  • [31] Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are Not Associated With Cyclosporine Pharmacokinetics Nor With Cyclosporine Clinical End Points After Renal Transplantation
    Bouamar, Rachida
    Hesselink, Dennis A.
    van Schaik, Ron H. N.
    Weimar, Willem
    MacPhee, Iain. A. M.
    de Fijter, Johan W.
    van Gelder, Teun
    THERAPEUTIC DRUG MONITORING, 2011, 33 (02) : 178 - 184
  • [32] Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects
    Kim, MK
    Cho, JY
    Lim, HS
    Hong, KS
    Chung, JY
    Bae, KS
    Oh, DS
    Shin, SG
    Lee, SH
    Lee, DH
    Min, B
    Jang, IJ
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (02) : 111 - 116
  • [33] Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects
    Myo-Kyoung Kim
    Joo-Youn Cho
    Hyeong-Seok Lim
    Kyoung-Seop Hong
    Jae-Yong Chung
    Kyun-Seop Bae
    Dal-Seok Oh
    Sang-Goo Shin
    Sang-Hun Lee
    Dong-Ho Lee
    Bumchan Min
    In-Jin Jang
    European Journal of Clinical Pharmacology, 2003, 59 : 111 - 116
  • [34] Lack of Effect of Brivanib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, Administered Intravenously and Orally in Healthy Participants
    Syed, Shariq
    Clemens, Pamela L.
    Lathers, Deanne
    Kollia, Georgia
    Dhar, Arindam
    Walters, Ian
    Masson, Eric
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (06) : 914 - 921
  • [35] Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects
    Shoaf, Susan E.
    Bricmont, Patricia
    Mallikaarjun, Suresh
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (04) : 579 - 587
  • [36] Effect of danshen extract on the activity of CYP3A4 in healthy volunteers
    Qiu, Furong
    Wang, Guangji
    Zhang, Rong
    Sun, Jianguo
    Jiang, Jian
    Ma, Yueming
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (06) : 656 - 662
  • [37] Effects of CYP3A4 inhibition/induction and OATP inhibition on the pharmacokinetics of atogepant in healthy adults
    Boinpally, Ramesh
    Chen, Wayne
    Mcgeeney, Danielle
    Trugman, Joel M.
    PAIN MANAGEMENT, 2023,
  • [38] Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes
    Anne Gardin
    Kasra Shakeri-Nejad
    Andrea Feller
    Felix Huth
    Srikanth Neelakantham
    Swati Dumitras
    European Journal of Clinical Pharmacology, 2019, 75 : 1565 - 1574
  • [39] Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes
    Gardin, Anne
    Shakeri-Nejad, Kasra
    Feller, Andrea
    Huth, Felix
    Neelakantham, Srikanth
    Dumitras, Swati
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (11) : 1565 - 1574
  • [40] Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone
    Kummer, Oliver
    Hammann, Felix
    Moser, Claudine
    Schaller, Olivier
    Drewe, Juergen
    Kraehenbuehl, Stephan
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (01) : 63 - 71
12345